Document:

THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR REGISTERED OR QUALIFIED UNDER ANY STATE SECURITIES
LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS SUCH SALE, TRANSFER, PLEDGE OR HYPOTHECATION
IS IN ACCORDANCE WITH SUCH ACT AND APPLICABLE STATE SECURITIES LAWS.

 

VILACTO BIO, INC.

8% SECURED NOTE

 

US $2,000,000Las Vegas, Nevada

November 9, 2018

 

For good and valuable consideration,
Vilacto Bio, Inc., a Nevada corporation, (“Maker”), hereby makes and delivers this 8% Secured Note (this
“Note”) in favor of 9 Heroes APS, or its assigns (“Holder”), and hereby agrees as
follows:

 

1.        Principal
Obligation and Interest. For value received, Maker promises to pay to Holder at Fabriksvej 48, 4700 Naestved.
Denmark, or at such other place as Holder may designate in writing, in currently available funds of the United States, the
principal amount of Two Million ($2,000,000) United States Dollars. Maker’s obligation under this Note shall accrue
simple interest at the rate of Eight Percent (8.0%) per year from the date hereof until paid in full. Interest
shall be computed on the basis of a 365-day year or 366-day year, as applicable, and actual days lapsed.

 

2.        Payment
Terms.

 

a.                  
All principal and accrued interest then outstanding shall be due and payable by the
Maker on or before Five (5) Years from the date hereof (the “Maturity Date”). 

 

b.                 
Accrued interest hereunder shall be due and payable from Maker to Holder on a semi-annual basis, with the first such payment
being due on January 1, 2019, and future payments being due each six (6) months thereafter until the Maturity Date or until earlier
redemption of this Note under the terms hereof.

 

c.                  
At any time before the Maturity Date, this Note may be prepaid or redeemed in whole, or in part on one or more occasions.

 

d.                 
All payments of interest hereunder may, at the sole option of the Maker, be paid in validly issued shares of common stock
in the Maker, par value $0.001, issued to Holder. Common stock issued to Holder as payment hereunder shall be valued at a price
per share equal to the average of the closing market prices for the Maker’s common stock during five (5) trading days immediately
preceding the due date for such payment.

 

    	 		 

    	 

    

 

e.                  
All payments shall be applied first to interest, then to principal and shall be credited
to the Maker's account on the date that such payment is physically received by the Holder. 

 

3.        Grant
of Security Interest. As collateral security for the prompt, complete, and timely satisfaction of all indebtedness, liabilities,
duties, and obligations of Maker to Holder evidenced by or arising under this Note, and including, without limitation, all principal
and interest payable under this Note and all attorneys’ fees, costs and expenses incurred by Maker in the collection or enforcement
of the same (collectively, the “Obligations”), Maker hereby pledges, assigns and grants to Holder a continuing
security interest and lien in all of Maker’s right, title and interest in and to the property, whether now owned or hereafter
acquired by Maker and whether now existing or hereafter coming into existence or acquired, including the proceeds of any disposition
thereof, described on Exhibit “A” attached hereto and incorporated herein by this reference (collectively, the “Collateral”).
As applicable, the terms of this Note with respect to Maker’s granting of a security interest in the Collateral to Holder
shall be deemed to be a security agreement under applicable provisions of the Uniform Commercial Code (“UCC”),
with Maker as the debtor and Holder as the secured party.

 

4.       Collateral
Agent.

 

a.Appointment
of Collateral Agent. Holder hereby irrevocably designates Pernille Steenfat as Collateral Agent (in such capacity, the “Collateral
Agent”). Holder hereby irrevocably authorizes the Collateral Agent to exercise all of the rights of the Holder under
the provisions of this Agreement, and any other instruments and agreements referred to herein, and to exercise such other powers
and take such other actions as are appropriate to protect the interests of the Holder in the Collateral. The provisions of this
Section are solely for the benefit of the Collateral Agent and Holder, and neither the Maker nor any of its subsidiaries or affiliates
shall have any rights as a third party beneficiary of any of the provisions hereof. In performing its functions and duties under
this Agreement, the Collateral Agent shall act solely as agent of the Holder and the Collateral Agent does not assume and shall
not be deemed to have assumed any obligation or relationship of agency or trust with the Maker, or for any of its subsidiaries
or affiliates.

 

b.Administration
of the Collateral. The Collateral Agent shall administer the lien on the Collateral for the benefit of the Holder in the manner
provided herein. The Collateral Agent shall exercise such rights and remedies with respect to the Collateral as are granted to
the Holder hereunder and applicable law and as shall be directed by the Holder. All directions of the Holder shall be determined
by those Holders holding a majority in total principal amount of the 8% Secured Notes then outstanding. Upon payment in full of
all obligations under this Note, the Collateral Agent shall promptly release any and all Collateral.

 

c.Reliance by
Collateral Agent. The Collateral Agent shall be entitled to rely, and shall be fully protected in relying, upon any note, writing,
resolution, notice, statement, certificate, telex, teletype or telecopier message, electronic mail, cablegram, radiogram, order
or other document, telephone message, or other electronic form of communication signed, sent or made by Holder and upon advice
and statements of legal counsel, independent accountants and other experts selected by the Collateral Agent.

 

    	 	2	 

    	 

    

 

d.Resignation
by Collateral Agent. The Collateral Agent may resign from the performance of all its respective functions and duties hereunder
and under related documents at any time by giving ten (10) days prior written notice to Holder and the Maker. Such resignation
shall take effect upon the appointment of a successor Collateral Agent.

 

5.        Perfection.
Upon the execution and delivery of this Note, Maker authorizes the Collateral Agent to file such financing statements and other
documents in such offices as shall be necessary or as the Collateral Agent may reasonably deem necessary to perfect and establish
the priority of the liens granted by this and related Notes, including any amendments, modifications, extensions or renewals thereof.
Maker agrees, upon the Collateral Agent’s request, to take all such actions as shall be necessary or as the Collateral Agent
may reasonably request to perfect and establish the priority of the liens granted by this Note, including any amendments, modifications,
extensions or renewals thereof. Maker shall cooperate fully with the Collateral Agent in establishing and maintaining Holder’s
perfection of Holder’s security interest in the Collateral, including notifying and keeping the Collateral Agent apprised
of the current location of all of the Collateral which consists of physical property and the status of all accounts payable or
similar rights which are a part of the Collateral.

 

6.        Representations
and Warranties of Maker. Maker hereby represents and warrants the following to Holder:

 

a.                  
Maker and those executing this Note on its behalf have the full right, power, and authority to execute, deliver and perform
the Obligations under this Note, which are not prohibited or restricted under the articles of incorporation or bylaws of Maker.
This Note has been duly executed and delivered by an authorized officer of Maker and constitutes a valid and legally binding obligation
of Maker enforceable in accordance with its terms.

 

b.                 
The execution of this Note and Maker’s compliance with the terms, conditions and provisions hereof does not conflict
with or violate any provision of any agreement, contract, lease, deed of trust, indenture, or instrument to which Maker is a party
or by which Maker is bound, or constitute a default thereunder or result in the imposition of any lien, charge, encumbrance, claim
or security interest of any nature whatsoever upon any of the Collateral.

 

c.                  
The security interest granted hereby in and to the Collateral constitutes a present, valid, binding and enforceable security
interest as collateral security for the Obligations, and, except as to leased equipment or purchase-money encumbrances existing
as of the date of this Note as expressly disclosed to Holder in writing, such interests, upon perfection, will be senior and prior
to any liens, encumbrances, charges, title defects, interests and rights of any others with respect to such Collateral.

 

d.                 
The security interest granted hereby shall be a first priority lien on the Collateral and no prior or superior liens, security
interests or encumbrances exist with respect to any part of the Collateral.

 

    	 	3	 

    	 

    

 

7.         Covenants
of Maker. For so long as any Obligations remain outstanding:

 

a.                  
Maker shall not sell, assign or transfer any of the Collateral, or any part thereof or interest therein except in the ordinary
course of its business;

 

b.                 
Maker shall pay or cause to be paid promptly when due all taxes and assessments on the Collateral.

 

8.       Representations
and Covenants of the Holder. The Maker has issued this Note in reliance upon the following representations and covenants
of the Holder:

 

a.                  
Investment Purpose. This Note and any common stock which may be issued as payment hereunder are acquired for investment
and not with a view to the sale or distribution of any part thereof, and the Holder has no present intention of selling or engaging
in any public distribution of the same except pursuant to a registration or exemption.

 

b.                 
Private Issue. The Holder understands (i) that this Note and any common stock which may be issued as payment
hereunder are not registered under the Securities Act of 1933 (the “1933 Act”) or qualified under applicable state
securities laws, and (ii) that the Maker is relying on an exemption from registration predicated on the representations set
forth in this Section 8.

 

c.                  
Financial Risk. The Holder has such knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment.

 

d.                 
Risk of No Registration. The Holder understands that if the Maker does not register with the Securities and Exchange
Commission pursuant to Section 12 of the Securities Exchange Act of 1934 (the "1934 Act"), or file reports pursuant
to Section 15(d) of the 1934 Act, or if a registration statement covering the securities under the 1933 Act is not in effect when
it desires to sell any of the common stock issued as payment hereunder, it may be required to hold such securities for an indefinite
period. The Holder also understands that any sale of this Note or any sale of common stock in the Maker which might be made by
Holder in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and conditions of that Rule.

 

9.        Use
of Collateral. For so long as no event of default shall have occurred and be continuing under this Note, Maker shall be
entitled to use and possess the Collateral and to exercise its rights, title and interest in all contracts, agreements, and licenses
subject to the rights, remedies, powers and privileges of Holder under this Note and to such use, possession or exercise not otherwise
constituting an event of default. Notwithstanding anything herein to the contrary, Maker shall remain liable to perform its duties
and obligations under the contracts and agreements included in the Collateral in accordance with their respective terms to the
same extent as if this Note had not been executed and delivered; the exercise by Holder of any right, remedy, power or privilege
in respect of this Note shall not release the Maker from any of its duties and obligations under such contracts and agreements;
and Holder shall have no duty, obligation or liability under such contracts and agreements included in the Collateral by reason
of this Note, nor shall Holder be obligated to perform any of the duties or obligations of Maker under any such contract or agreement
or to take any action to collect or enforce any claim (for payment) under any such contract or agreement.

 

    	 	4	 

    	 

    

 

10.        Defaults.
The following events shall be defaults under this Note:

 

a.        Maker’s
failure to remit any payment under this Note on before the date due, if such failure is not cured in full within ten (10) days
of written notice of default;

 

b.        Maker’s
failure to perform or breach of any non-monetary obligation or covenant set forth in this Note or in the Agreement if such failure
is not cured in full within fifteen (15) days following delivery of written notice thereof from Holder to Maker;

 

c.        If
Maker is dissolved, whether pursuant to any applicable articles of incorporation or bylaws, and/or any applicable laws, or otherwise;

 

d.
       The commencement of any action or proceeding which affects the Collateral or title thereto
or the interest of Holder therein, including, but not limited to eminent domain, insolvency, code enforcement or arrangements or
proceedings involving a bankrupt or decedent;

 

e.
       Any default of the Maker’s debt obligations currently existing or hereinafter acquired;

 

f.
       The entry of a decree or order by a court having jurisdiction in the premises adjudging
the Maker bankrupt or insolvent, or approving as properly filed a petition seeking reorganization, arrangement, adjustment or composition
of or in respect of the Maker under the federal Bankruptcy code or any other applicable federal or state law, or appointing a receiver,
liquidator, assignee or trustee of the Maker, or any substantial part if its property, or ordering the winding up or liquidation
of its affairs, and the continuance of any such decree or order un-stayed and in effect for a period of twenty (20) days; or

 

g.
       Maker’s institution of proceedings to be adjudicated a bankrupt or insolvent, or
the consent by it to the institution of bankruptcy or insolvency proceedings against it, or its filing of a petition or answer
or consent seeking reorganization or relief under the federal Bankruptcy Code or any other applicable federal or state law, or
its consent to the filing of any such petition or to the appointment of a receiver, liquidator, assignee or trustee of the company,
or of any substantial part of its property, or its making of an assignment for the benefit of creditors or the admission by it
in writing of its inability to pay its debts generally as they become due, or the taking of corporate action by the Maker in furtherance
of any such action.

 

11.       Rights
and Remedies of Holder. Upon the occurrence of an event of default by Maker under this Note,
then, in addition to all other rights and remedies at law or in equity, Holder may exercise any one or more of the following rights
and remedies:

 

a.        Accelerate
the time for payment of all amounts payable under this Note by written notice thereof to Maker, whereupon all such amounts shall
be immediately due and payable.

 

b.        Pursue
and enforce all of the rights and remedies provided to a secured party with respect to the Collateral under the Uniform Commercial
Code.

 

    	 	5	 

    	 

    

 

c.        Make
such appearance, disburse such sums, and take such action as Holder deems necessary, in its sole discretion, to protect Holder’s
interest, including but not limited to (i) disbursement of attorneys’ fees, (ii) entry upon the Maker’s property to
make repairs to the Collateral, and (iii) procurement of satisfactory insurance. Any amounts disbursed by Holder pursuant to this
Section, with interest thereon, shall become additional indebtedness of the Maker secured by this Note and shall be immediately
due and payable and shall bear interest from the date of disbursement at the default rate stated in this Note. Nothing contained
in this Section shall require Holder to incur any expense or take any action.

 

d.        Require
Maker to assemble the Collateral and make it available to the Maker at the place to be designated by the Holder which is reasonably
convenient to both parties. The Holder may sell all or any part of the Collateral as a whole or in part either by public auction,
private sale, or other method of disposition. The Holder may bid at any public sale on all or any portion of the Collateral. Unless
the Collateral threatens to decline speedily in value, Holder shall give Maker reasonable notice of the time and place of any public
sale or of the time after which any private sale or other disposition of the Collateral is to be made, and notice given at least
10 days before the time of the sale or other disposition shall be conclusively presumed to be reasonable.

 

e.        Pursue
any other rights or remedies available to Holder at law or in equity.

 

12.       Full
Recourse. The liability of Maker for the Obligations shall not be limited to the Collateral, and Maker shall have full
liability therefor beyond the Collateral.

 

13.        Representation
of Counsel. Maker acknowledges that they have consulted with or have had the opportunity to consult with their legal counsel
prior to executing this Note. This Note has been freely negotiated by Maker and Holder and any rule of construction to the effect
that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Note.

 

14.        Choice
of Laws; Actions. This Note shall be constructed and construed in accordance with the internal substantive laws of the
State of Nevada, without regard to the choice of law principles of said State. Maker acknowledges that this Note has been negotiated
in Clark County, Nevada. Accordingly, the exclusive venue of any action, suit, counterclaim or cross claim arising under, out of,
or in connection with this Note shall be the state or federal courts in Clark County, Nevada. Maker hereby consents to the personal
jurisdiction of any court of competent subject matter jurisdiction sitting in Clark County, Nevada.

 

15.        Usury
Savings Clause. Maker expressly agrees and acknowledges that Maker and Holder intend and agree that this Note shall not
be subject to the usury laws of any state other than the State of Nevada. Notwithstanding anything contained in this Note to the
contrary, if collection from Maker of interest at the rate set forth herein would be contrary to applicable laws, then the applicable
interest rate upon default shall be the highest interest rate that may be collected from Maker under applicable laws at such time.

 

    	 	6	 

    	 

    

 

16.        Costs
of Collection. Should the indebtedness represented by this Note, or any part hereof, be collected at law, in equity, or
in any bankruptcy, receivership or other court proceeding, or this Note be placed in the hands of any attorney for collection after
default, Maker agrees to pay, in addition to the principal and interest due hereon, all reasonable attorneys’ fees, plus
all other costs and expenses of collection and enforcement, including any fees incurred in connection with such proceedings or
collection of the Note and/or enforcement of Holder’s rights with respect to the administration, supervision, preservation
or protection of, or realization upon, any Collateral securing payment hereof.

 

17.        Miscellaneous.

 

a.        This
Note shall be binding upon Maker and shall inure to the benefit of Holder and its successors, assigns, heirs, and legal representatives.

 

b.        Any
failure or delay by Holder to insist upon the strict performance of any term, condition, covenant or agreement of this Note, or
to exercise any right, power or remedy hereunder shall not constitute a waiver of any such term, condition, covenant, agreement,
right, power or remedy.

 

c.        Any
provision of this Note that is unenforceable shall be severed from this Note to the extent reasonably possible without invalidating
or affecting the intent, validity or enforceability of any other provision of this Note.

 

d.        This
Note may not be modified or amended in any respect except in a writing executed by the party to be charged.

 

e.        Time
is of the essence.

 

18.       Notices.
All notices required to be given under this Note shall be given to each of the parties at such address as a party may designate
by written notice to the other party.

 

Notices may be transmitted
by facsimile, certified mail, private delivery, or any other commercially reasonable means, and shall be deemed given upon receipt
by the Party to whom they are addressed.

 

19.       Waiver
of Certain Formalities. All parties to this Note hereby waive presentment, dishonor,
notice of dishonor and protest. All parties hereto consent to, and Holder is hereby expressly authorized to make, without notice,
any and all renewals, extensions, modifications or waivers of the time for or the terms of payment of any sum or sums due hereunder,
or under any documents or instruments relating to or securing this Note, or of the performance of any covenants, conditions or
agreements hereof or thereof or the taking or release of collateral securing this Note. Any such action taken by Holder shall not
discharge the liability of any party to this Note.

 

    	 	7	 

    	 

    

 

IN WITNESS WHEREOF, this Note has been
executed effective the date and place first written above.

 

	
        Vilacto Bio, Inc. “Maker”:

         

         

        By: /s/ Gert Andersen 

         

         

         
	
        “Holder”:

         

         

        /s/ Gert Andersen

         

        Print name: Gert Andersen

         

    	 	8	 

    	 

    

 

Exhibit “A”

 

Collateral

 

Each and all of the following
in which Vilacto Bio, Inc., a Nevada Corporation, has any right, title, or interest, regardless of the manner in which such
items are formally held or titled; all as defined in the Nevada Uniform Commercial Code - Secured Transactions (Nevada Revised
Statutes (“NRS”) §§ 104.9101 et. seq.) as of the date of the Note, and as the same may be amended hereafter:

 

(1) Accounts, as defined
in NRS 104.9102(1)(a)

 

(2) Cash proceeds, as defined
in NRS 104.9102(1)(I)

 

(3) Chattel paper, as defined
in NRS 104.9102(1)(k)

 

(4) Commercial tort claims,
as defined in NRS 104.9102(1)(m)

 

(5) Commodity accounts
and commodity contracts, as defined in NRS 104.9102(1)(n) and NRS 104.9102(1)(o), respectively,

 

(6) Deposit accounts, as
defined in NRS 104.9102(1)(cc)

 

(7) Documents, as defined
in NRS 104.9102(1)(dd)

 

(8) Electronic chattel
paper, as defined in NRS 1049102(1)(ee)

 

(9) Equipment, as defined
in NRS 104.9102(1)(gg)

 

(10) General intangibles,
as defined in NRS 104.9102(1)(pp)

 

(11) Goods, as defined
in NRS 104.9102(1)(rr)

 

(12) Instruments, as defined
in NRS 104.9102(1)(uu)

 

(13) Inventory, as defined
in NRS 104.9102(1)(vv)

 

(14) Investment property,
as defined in NRS 104.9102(1)(ww)

 

(15) Letter-of-credit right,
as defined in NRS 104.9102(1)(yy)

 

(16) Noncash proceeds,
as defined in NRS 104.9102(1)(fff)

 

(17) Payment intangible,
as defined in NRS 104.9102(1)(iii)

 

(18) Proceeds, as defined
in NRS 104.9102(1)(lll)

 

(19) Promissory notes,
as defined in NRS 104.9102(1)(mmm)

 

(20) Record, as defined
in NRS 104.9102(1)(qqq)

 

(21) Software, as defined
in NRS 104.9102(1)(www)

 

(22) Supporting obligations,
as defined in NRS 104.9102(1)(yyy)

 

(23) Tangible chattel paper,
as defined in NRS 104.9102(1)(zzz)

 

(24) The following, as
defined in NRS 104.9102(2): certificated securities, contracts for sale, leases, lease agreements, lease contracts, leasehold interests,
letters of credit, negotiable instruments, notes, proceeds of letters of credit, securities, security certificates, security entitlements,
and uncertificated securities.

 

In addition, the Collateral
shall include all copyrights, all patents and patent applications (including the inventions and improvements described and claimed
therein together with the reissues, divisions, continuations, renewals, extensions and continuations in-part thereof), all trade
names, trademarks and service marks, logos, trademark and service mark registrations (including all renewals of trademark and service
mark registrations, and all rights corresponding thereto throughout the world together, in each case, with the goodwill of the
business connected with the use of, and symbolized by, each such trade name, trademark and service mark, but excluding any such
registration that would be rendered invalid, abandoned, void or unenforceable by reason of its being included as part of the Collateral),
all inventions, processes, production methods, proprietary information, know-how and trade secrets, all licenses or user or other
agreements granted to Vilacto Bio, Inc. with respect to any of the foregoing, in each case whether now or hereafter owned or used
(including the licenses or other agreements with respect to any of the foregoing).

 

    	 	9termination
and release agreement

 

This
Termination and Release Agreement (“Agreement”) is entered into as of this 8th day of November, 2018, by and among
Vilacto Bio, Inc., a Nevada corporation (the “Vilacto”), Pharma GP APS, a Denmark corporation, and its sole shareholder,
9 Heroes APS, a Denmark corporation (together “Pharma GP”).

 

WHEREAS,
on or about April 19, 2017, we entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Pharma GP and
its sole shareholder, 9 Heroes APS, a Denmark corporation, pursuant to which we agreed to purchase all of the outstanding shares
of Pharma GP for the purchase price of $6,000,000.00, payable as $3,000,000.00 in cash and the balance in shares of our common
stock;

 

WHEREAS,
the closing of the Purchase Agreement was originally scheduled to occur on May 31, 2017; however, Vilacto has been unable to raise
money needed to pay the purchase price under the Purchase Agreement;

 

WHEREAS,
the parties now desire to terminate and release each other and otherwise settle, compromise, dispose of, and release with finality,
all claims, demands and causes of action, arising out of the Purchase Agreement dated April 19, 2017;

 

NOW,
THEREFORE, in exchange for consideration, the adequacy of which is hereby acknowledged, the parties agree as follows:

 

	Termination.
Subject to the terms and conditions of this Agreement, as of the date hereof, the Parties hereby terminate the Purchase Agreement
and any and all rights, obligations or duties created thereunder.

 

	Coordination.
The parties agree to take whatever measures are necessary return to their respective positions as if the Purchase Agreement
were never executed.

 

	Mutual
Release. Except for the obligations set forth in this Agreement, each party hereby releases, remises, acquits and forever
discharges any other party to this Agreement and their related or controlled entities, and all of their directors, officers, members,
managers, partners, employees, servants, attorneys, assigns, heirs, successors, agents and representatives, past and present,
and the respective successors, executors, administrators and any legal and personal representatives of each of the foregoing,
and each of them, from any and all claims, demands, actions, causes of action, debts, liabilities, rights, contracts, obligations,
duties, damages, costs, expenses or losses, of every kind and nature whatsoever, and by whomever asserted, whether at this time
known or suspected, or unknown or unsuspected, anticipated or unanticipated, direct or indirect, fixed or contingent, or which
may presently exist or which may hereafter arise or become known, in law or in equity, in the nature of an administrative proceeding
or otherwise, for or by reason of any event, transaction, matter or cause whatsoever, with respect to, in connection with or arising
out of the Purchase Agreement or otherwise.

 

It
is understood by the parties that the facts with respect to which the foregoing release is given may hereafter turn out to be
other than or different from the facts now known to a party or the parties or believed by a party or the parties to be true, and
each party therefore expressly assumes the risk of the facts turning out to be so different and agrees that the foregoing release
shall be in all respects effective and not subject to termination or rescission by any such difference in facts.

 

    	 		 

    	 

    

 

	No Assignment.
The parties to this Agreement represent and warrant that neither they or their affiliated persons or entities have assigned or
transferred any claim or interest herein or authorized any other person or entity to assert any claim or claims on its behalf with
respect to the subject matter of this Agreement.

 

	Non-Disparagement.
The parties agree not to make any oral or written statements or otherwise take any action that is intended or may reasonably be
expected to disparage the reputation, business, prospects or operations of any other party to this Agreement.

 

	Confidentiality.
The parties agree that they will keep confidential all information and trade secrets of one another or any of its subsidiaries
or affiliates and will not disclose such information to any person without written prior approval or use such information for any
purpose. It is understood that for purposes of this Agreement the term “confidential information” is to be construed
broadly to include all material nonpublic or proprietary information. Vilacto shall promptly return any documents, records, data,
books or materials of Pharma GP or its subsidiaries or affiliates in its possession or control and any of its work papers containing
confidential information or trade secrets of Pharma GP or its subsidiaries or affiliates.

 

	Cooperation.
Each of the parties hereby agree to perform any and all acts and to execute and deliver any and all documents reasonably necessary
or convenient to carry out the intent and the provisions of this Agreement.

 

	Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada, without reference to the
principles of conflict of laws.

 

	Complete Agreement.
This Agreement represents the complete agreement among the parties concerning the subject matter in this Agreement and supersedes
all prior agreements or understandings, written or oral, including the Agreement, the Security Agreements, the Advances, or otherwise.
This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective
successors and legal representatives.

 

	Voluntary Agreement.
This Agreement has been entered into voluntarily and not as a result of coercion, duress, or undue influence. The parties acknowledge
that they have read and fully understand the terms of this Agreement and have been advised to consult with an attorney before executing
this Agreement.

 

	Successors and Assigns.
This Agreement shall be binding and inure to the benefit of the parties hereto, their predecessors, parents, subsidiaries and affiliated
corporations, all officers, directors, shareholders, agents, employees, attorneys, assigns, successors, heirs, executors, administrators,
and legal representatives of whatsoever kind or character in privity therewith.

 

	Counterparts.
This Agreement may be executed in counterparts, one or more of which may be facsimiles, but all of which shall constitute one and
the same Agreement. Facsimile signatures of this Agreement shall be accepted by the parties to this Agreement as valid and binding
in lieu of original signatures.

 

	Time for Performance.
The parties understand that time is of the essence with respect to each and every act required by this Agreement. Failure to perform
any provision hereof in strict accordance with the Agreement shall be deemed a material breach of the Agreement.

    	 	2	 

    	 

    

 

The
parties to this Agreement have executed this Agreement as of the day and year first written above.

 

VILACTO
BIO INC.

By
/s/ Gert Andersen

Printed
Name: Gert Andersen

Title:
CEO

 

PHARMA
GP APS

By
/s/ Gert Andersen

Printed
Name: Gert Andersen

Title:
CEO

 

9
HEROES APS

By
/s/ Gert Andersen

Printed
Name: Gert Andersen

Title:
CEO

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]